IP Library › Granted Patent US 7,439,228
Granted Patent B2
US 7,439,228 · App. 09/798,026 · Granted Oct 21, 2008

Bioactive peptides

Assignee: Lytix Biopharma AS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,439,228
App. No.
09/798,026
Granted
Oct 21, 2008
Kind
B2
Abstract

The present invention provides a cytotoxic 7 to 25-mer peptide with three or more catonic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.

Claims (8)

1. A cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof, wherein the non-genetic bulky and lipophilic amino acid has an R group that has at least 9 non-hydrogen atoms.

2. A peptide as claimed in claim 1 wherein the R group comprises 2 or more closed rings of 5 or 6 atoms.

3. A peptide as claimed in claim 1 wherein the non-genetic bulky and lipophilic amino acid is a modified aromatic residue.

4. A peptide as claimed in claim 3 wherein the aromatic residue is tryptophan.

5. A peptide as claimed in claim 3 wherein the aromatic residue is modified by a protecting group.

6. A peptide as claimed in claim 1 which is amphipathic in nature.

7. A pharmaceutical composition comprising a peptide as claimed in claim 1 together with a physiologically acceptable excipient.

8. A peptide as claimed in claim 1 wherein the non-genetic bulky and lipophilic amino acid has an R group that has at least 12 non-hydrogen atoms.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME, PREVIOUSLY RECORDED AT REEL 017811, FRAME 0182. Recorded Mar 11, 2008
From: ALPHARMA AS
To: LYTIX BIOPHARMA AS
Reel/Frame 020671/0139 →
RECORD TO CORRECT THE ASSIGNEE, PREVIOUSLY RECORDED ON REEL 017811 FRAME 0182. Recorded Mar 11, 2008
From: ALPHARMA AS
To: LYTIX BIOPHARMA AS
Reel/Frame 020753/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2006
From: ALPHARMA AS
To: LYTIX BIOPHARMA
Reel/Frame 017811/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2006
From: SVENDSEN, JOHN SIGURD; REKDAL, OYSTEIN; SVEINBJORNSSON, BALDUR; VORLAND, LARS
To: ALPHARMA AS
Reel/Frame 017570/0404 →
Priority Claims (1)
GB 9818938.4 · Aug 28, 1998 · national
Continuity (2)
Continuation PCTGB990285000 · Aug 31, 1999
Related Publication 20030148936A1 · Aug 7, 2003